David Sinclair on AI Drug Discovery, GLP-1 Side Effects, and Longevity Investing | Q&A EP #251
Filmed live at the 2026 Abundance360 Summit, Sinclair covers how AI is compressing drug-discovery timelines from decades to months, the real risks and benefits of GLP-1 agonists for longevity, and where the smartest longevity capital is flowing. He also shares his updated biological-age reversal data and near-term timeline for a clinically approved age-reversal intervention.
Related molecules